Clinical trials: sponsored by Jemincare
Hyperphosphatemia
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- Trial name
- NCT06664125
- Testing
- JMKX003002 will be administered orally, Sevelamer carbonate
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Jemincare
Chronic Spontaneous Urticaria
Trial of JYB1904 in Chronic Spontaneous Urticaria.
This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.
- Trial name
- NCT06509334
- Testing
- JYB1904, Omalizumab
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Jemincare
ADPKD (autosomal Dominant Polycystic Kidney Disease)
Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.
- Trial name
- NCT06658964
- Testing
- Cohort 1: JMKX003142 and itraconazole, Cohort 2: JMKX003142 and rifampicin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
Trial of JMKX003801 in Healthy Participants
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003801 Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Dose in Chinese Healthy Adult…
- Trial name
- NCT06549309
- Testing
- JMKX003801
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Jemincare
Renal Cell Carcinoma Metastatic
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
- Trial name
- NCT06321250
- Testing
- JMKX003948
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jemincare
Solid Tumor, Adult
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
- Trial name
- NCT06473948
- Testing
- JMKX001899
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy, Drug-Drug Interaction
A DDI Study of JMKX000623 and Metformin Hydrochloride
A phase 1, single center, 1 sequence, 3 period, open label, multiple doses study to evaluate the drug-drug interaction of JMKX000623 tablet and metformin.
- Trial name
- NCT06066060
- Testing
- JMKX000623, Metformin
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jemincare
Diabetic Peripheral Neuropathic Pain
Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain
A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX000623 in Participants with Diabetic Peripheral Neuropathic Pain
- Trial name
- NCT06221241
- Testing
- JMKX000623, Pregabalin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jemincare
Solid Tumor, Adult
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects.
- Trial name
- NCT06348290
- Testing
- JMKX001899, Itraconazole, Midazolam
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy Adult
Study of JMKX003142 Injection in Chinese Healthy Subjects
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy…
- Trial name
- NCT06344533
- Testing
- JMKX003142 Injection
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Jemincare
Safety and Tolerability
Phase 1 Clinical Study of JMKX003142 Tablets
Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JMKX003142 tablets administered randomly, double-blind, placebo-controlled single and multiple times in healthy adult subjects…
- Trial name
- NCT06079541
- Testing
- JMKX003142 will be administered orally
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Jemincare
Lupus Erythematosus, Systemic
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care…
- Trial name
- NCT05967520
- Testing
- JMKX000189
- Where
- 17 sites in China
- Volunteers
- 48 people
- Sponsor
- Jemincare
Malignant Pleural Effusion
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
- Trial name
- NCT05923515
- Testing
- JMKX000197
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jemincare
Solid Tumor
JYB1907 in Subjects With Advanced Solid Tumors
A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid…
- Trial name
- NCT05821595
- Testing
- JYB1907
- Volunteers
- 30 people
- Sponsor
- Jemincare
Healthy
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.
- Trial name
- NCT05449535
- Testing
- JYB1904, Omalizumab
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jemincare
Safety and Tolerability
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
Safety, tolerability, pharmacokinetics, and pharmacodynamics of JMKX003002 in single and multiple ascending dose randomized，doubled-blind phase 1 study in healthy subjects
- Trial name
- NCT05907382
- Testing
- JMKX003002 will be administered orally
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jemincare
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.
- Conditions
- Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Glomerulonephritis
- Trial name
- NCT04349683
- Testing
- Jinshuibao
- Volunteers
- 332 people
- Sponsor
- Jemincare